Inhibition of imatinib transport by uremic toxins during renal failure

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4226-4227

  Franke, Ryan M ^a   Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXY 4 METHYL 5 PROPYL 2 FURAN PROPIONIC ACID; 4 AMINOHIPPURIC ACID; IMATINIB; PACLITAXEL; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UREMIC TOXIN;

AREA UNDER THE CURVE; BILIARY EXCRETION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INHIBITION; DRUG TRANSPORT; DRUG UPTAKE; EXPERIMENTAL MODEL; HUMAN; KIDNEY FAILURE; LETTER; LIVER FAILURE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER FAILURE; NEOPLASMS; ORGANIC ANION TRANSPORTERS; PACLITAXEL; PIPERAZINES; PYRIMIDINES; XENOPUS LAEVIS;

EID: 51649092790     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.4390     Document Type: Letter

References (16)

1. Ramanathan RK, Egorin MJ, Takimoto CH, et al: Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:563-569, 2008
2. Gibbons J, Egorin MJ, Ramanathan RK, et al: Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:570-576, 2008
3. Judson IR: Imatinib for patients with liver or kidney dysfunction: No need to modify the dose. J Clin Oncol 26:521-522, 2008
4. Peng B, Lloyd P, Schran H: Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894, 2005
5. Nolin TD, Naud J, Leblond FA, et al: Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898-903, 2008
6. Leblond FA, Petrucci M, Dube P, et al: Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13:1579-1585, 2002
7. Leblond F, Guevin C, Demers C, et al: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12:326-332, 2001
8. Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124:96-104, 1994
9. Niwa T, Aiuchi T, Nakaya K, et al: Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 39:92-96, 1993
10. Lim CF, Bernard BF, de Jong M, et al: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 76:318-324, 1993
11. Henderson SJ, Lindup WE: Renal organic acid transport: Uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 263:54-60, 1992
12. Sun H, Huang Y, Frassetto L, et al: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 32:1239-1246, 2004
13. Hu S, Franke RM, Filipski KK, et al: Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14:3141-3148, 2008
14. Smith NF, Acharya MR, Desai N, et al: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4:815-818, 2005
15. Gelderblom H, Verweij J, Brouwer E, et al: Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. Drug Metab Dispos 27:1300-1305, 1999
16. Woo MH, Gregornik D, Shearer PD, et al: Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol 43:92-96, 1999